Advancements in Computer-Aided Drug Design: Targeting the PD-1/PD-L1 Immune Checkpoint with Small Molecule Inhibitors

Cancer continues to be a major global health burden, with conventional therapies often limited by relapse, resistance, and toxicity. Immunotherapy, particularly PD-1/PD-L1 checkpoint blockade, has transformed treatment by reactivating antitumor T-cell responses. While monoclonal antibodies against PD-1/PD-L1 have shown remarkable success, their high cost, intravenous delivery, immune-related side effects, and resistance highlight the need for alternatives. Small molecule inhibitors (SMIs) offer advantages such as oral bioavailability, improved tumor penetration, reduced immunogenicity, and lower production costs. However, the broad PD-1/PD-L1 interface poses design challenges. Recent advances in computer-aided drug design (CADD)—including docking, pharmacophore modeling, QSAR, virtual screening, and in silico ADME/T prediction—are driving progress in developing effective SMIs. This review outlines the biology of the PD-1/PD-L1 axis, the evolution of checkpoint therapy, and current efforts to harness CADD for novel small molecule inhibitors.

PD-1, PD-L1, immune checkpoint, cancer immunotherapy

1. New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape - ScienceDirect [Google Scholar] [Crossref]

2. Progress in small-molecule inhibitors targeting PD-L1. Jindan Xu , Yuanfang Kong , Pengbo Zhu, Mingyan Du, Xuan Liang , Yan Tong , Xiaofei Li, Chunhong Dong [Google Scholar] [Crossref]

3. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Lingjiao Meng, Haotian Wu, Jiaxiang Wu, Ping’an Ding, Jinchen He, Meixiang Sang & Lihua Liu [Google Scholar] [Crossref]

4. Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction. Damian Muszak,Ewa Surmia, Jacek Plewka,Katarzyna Magiera-Mularz, Justyna Kocik-Krol, Bogdan Musielak, Dominik Sala, Radoslaw Kitel, Malgorzata Stec, Kazimierz Węglarczyk, Maciej Siedlar, Alexander Dömling, Lukasz Skalniak,Tad A. Holak, [Google Scholar] [Crossref]

5. 1,5-Disubstituted tetrazoles as PD-1/PD-L1 antagonists† Robin van der Straat,a Rosalie Draijer,a Ewa Surmiak, b Roberto Butera,a Lennart Land,a Katarzyna Magiera-Mularz,b Bogdan Musielak,b Jacek Plewka, b Tad A. Holakb and Alexander Dömling [Google Scholar] [Crossref]

6. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Kankana Bardhan¹.2, Theodora Anagnostou³ and Vassiliki A. Boussiotis [Google Scholar] [Crossref]

7. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and futureconsiderationsYongshuai Jiang a *, Ming Chenb *, Hong Nie a,c , and Yuanyang Yuan [Google Scholar] [Crossref]

8. Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis by Sarfaraz K. Niazi and Zamara Mariam [Google Scholar] [Crossref]

9. Modern drug discovery applications for the identification of novel candidates for COVID-19 infections.Rani, Ishaa; Kalsi, Avijit; Kaur, Gagandeepc; Sharma, Pankaj; Gupta, Sumeeta; Gautam, Rupesh K.b,**; Chopra, Hiteshe; Bibi, Shabanaff; Ahmad, Syed Umairh; Singh, Inderbire; Dhawan, Manishi,j; Emran, Talha Bink,l, [Google Scholar] [Crossref]

10. Discovery of small-molecule PD-1/PD-L1 antagonists through combined virtual screening and experimental validationMichelle DiFrancesco a, Jeremy Hofer b, Abhay Aradhya b, Jeffrey Rufinus b, John Stoddart b, Stephen Finocchiaro a, Jabari Mani a, Sean Tevis a, Michael Visconti a, Griffin Walawender a, Juliette DiFlumeri a, Elena Fattakhova a, Sachin P. Patil. [Google Scholar] [Crossref]

11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Kathleen M. Mahoney, PhD∙ Gordon J. Freeman, David F. McDermott, [Google Scholar] [Crossref]

12. Regulation and Function of the PD-L1 Checkpoint. Chong Sun2 ∙ Riccardo Mezzadra2 ∙ Ton N. Schumacher. [Google Scholar] [Crossref]

13. Present and future challenges in therapeutic designing using computational approaches.Sonal Prasad , Aashna Srivastava , Namami Singh ,Himadri Singh, Rohit Saluja , Ashok Kumar ,Neelam Yadav, Tabish Qidwai [Google Scholar] [Crossref]

14. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Yongshuai Jiang a,*, Ming Chen b,*, Hong Nie a,c,✉, Yuanyang Yuan. [Google Scholar] [Crossref]

15. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2, Krzysztof M. Zak1,2 ∙ Przemyslaw Grudnik1,2 ∙ Katarzyna Magiera3 ∙ Alexander Dömling4 ∙ Grzegorz Dubin1,2 ∙ Tad A. Holak1,3,5 [Google Scholar] [Crossref]

16. PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. Arash Salmaninejad 1 2, Saeed Farajzadeh Valilou 3, Arezoo Gowhari Shabgah 4, SaeedAslani 5, Malihe Alimardani 2, Alireza Pasdar 2 6, Amirhossein Sahebkar [Google Scholar] [Crossref]

17. A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules by Marialuigia Fantacuzzi *ORCID,Roberto PaciottiORCID andMariangela Agamennone [Google Scholar] [Crossref]

18. Computer Aided Drug Design: Success and Limitations Hassan Baig, Mohammad; Ahmad, Khurshid; Roy, Sudeep; Mohammad Ashraf, Jalaluddin; Adil, Mohd; Haris Siddiqui, Mohammad; Khan, Saif; Amjad Kamal, Mohammad; Provazník, Ivo; Choi, Inho [Google Scholar] [Crossref]

19. Progress in small-molecule inhibitors targeting PD-L1. Jindan Xu , Yuanfang Kong , Pengbo Zhu, Mingyan Du, Xuan Liang , Yan Tong , Xiaofei Li, Chunhong Dong [Google Scholar] [Crossref]

20. Discovery of small-molecule PD-1/PD-L1 antagonists through combined virtual screening and experimental validation Michelle DiFrancesco a, Jeremy Hofer b, Abhay Aradhya b, Jeffrey Rufinus b, John Stoddart b, Stephen Finocchiaro a, Jabari Mani a, Sean Tevis a, Michael Visconti a, Griffin Walawender a, Juliette DiFlumeri a, Elena Fattakhova a, Sachin P. Patil a [Google Scholar] [Crossref]

21. Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint InhibitorsPatrícia S. Sobral1,2,3, Vanessa C. C. Luz2,3, João M. G. C. F. Almeida2, Paula A. Videira2,3and Florbela Pereira1, [Google Scholar] [Crossref]

22. Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development Pottayil G. Sasikumar,Murali Ramachandra [Google Scholar] [Crossref]

23. Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges Sadique A Javed, Asim Najmi, Waquar Ahsan, Khalid Zoghebi [Google Scholar] [Crossref]

• QbD Approach to Hplc Method Development and Validation of the Simultaneous Estimation of Sulbactum and Durlobactum in Pharmaceutical Dosage Form
• A Review on an Evaluation of a Liposomal Hydrogel for Combined Minoxidil and Tretinoin Delivery in Androgenetic Alopecia
• Qualitative Screening and Analysis of Lunasia amara Blanco (Tawal-ulad) Ethanolic Leaves Extract as Potential Anti-Angiogenic Inhibitors Using the Chorioallantoic Membrane Assay on Mallard Duck Embryo
• A Comprehensive Review on Calotropis Procera on Its Analgesic Activity
• Formulation, Characterization and In-Vitro Evaluation of Curcumin Loaded Liposome for Colon Drug delivery